It is made available under a CC-BY-ND 4.0 International license .

1 **TITLE**

- 2 The co-occurrence of genetic variants in the TYR and OCA2 genes confers
- 3 susceptibility to albinism

5	AUTHOR LIST & AFFILIATIONS
6	David J. Green ¹ , Vincent Michaud ^{2,3} , Eulalie Lasseaux ² , Claudio Plaisant ² , UK
7	Biobank Eye and Vision Consortium, Tomas Fitzgerald ⁴ , Ewan Birney ⁴ , Graeme C.
8	Black ^{1,5,#} , Benoît Arveiler ^{2,3,#} , Panagiotis I. Sergouniotis ^{1,4,5,6}
9	
10	¹ Division of Evolution, Infection and Genomics, School of Biological Sciences,
11	Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
12 13	² Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux,
14	France.
15 16	³ INSERM U1211, Rare Diseases, Genetics and Metabolism, University of
17	Bordeaux, Bordeaux, France.
18 19	⁴ European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-
20	EBI), Wellcome Genome Campus, Cambridge, UK.
21 22	5 Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester
23	University NHS Foundation Trust, Manchester, UK.
24 25	⁶ Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust,
26	Manchester, UK.
27	
28	
29	# These authors contributed equally: Graeme C. Black, Benoît Arveiler

It is made available under a CC-BY-ND 4.0 International license .

- 30
- 31 Correspondence to
- 32 Panagiotis I. Sergouniotis (panagiotis.sergouniotis@manchester.ac.uk).

It is made available under a CC-BY-ND 4.0 International license .

34 ABSTRACT

35

36 Although rare genetic conditions are mostly caused by DNA sequence alterations 37 that functionally disrupt individual genes, large-scale studies using genome 38 sequencing have started to unmask additional complexity. Understanding how 39 combinations of variants in different genes shape human phenotypes is expected to 40 provide important insights into the clinical and genetic heterogeneity of rare 41 disorders. We used albinism, an archetypal rare condition associated with 42 hypopigmentation, as an exemplar for the study of genetic interactions. We analysed 43 data from the Genomics England 100,000 Genomes Project alongside a cohort of 44 1,120 individuals with albinism, and investigated the effect of dual heterozygosity for 45 the combination of two established albinism-related variants: TYR:c.1205G>A 46 (p.Arg402Gln) [rs1126809] and OCA2:c.1327G>A (p.Val443lle) [rs74653330]. As 47 each of these changes alone is insufficient to cause disease when present in the 48 heterozygous state, we sought evidence of synergistic effects. We found that, when 49 both variants are present, the probability of receiving a diagnosis of albinism is 50 significantly increased (odds ratio 12.8; 95% confidence interval 6.0 – 24.7; p-value 51 2.1 x 10⁻⁸). Further analyses in an independent cohort, the UK Biobank, supported 52 this finding and highlighted that heterozygosity for the TYR:c.1205G>A and 53 OCA2:c.1327G>A variant combination is associated with statistically significant 54 alterations in visual acuity and central retinal thickness (traits that are considered 55 albinism endophenotypes). The approach discussed in this report opens up new 56 avenues for the investigation of oligogenic patterns in apparently Mendelian 57 disorders.

58

59 **KEYWORDS**: epistasis, digenic, oligogenic, bi-locus, genetic interaction

It is made available under a CC-BY-ND 4.0 International license .

60 MAIN TEXT

61 **INTRODUCTION**

62

63 An individual affected by a condition that appears to segregate as a Mendelian trait,

- 64 would be expected to carry large-effect genetic variation in a single gene/locus.
- 65 However, for a significant proportion of affected probands, single-gene-centric
- 66 genomic analyses fail to identify a clear genetic diagnosis.¹⁻⁶ Although this diagnostic
- and knowledge gap is, to a degree, due to imperfect phenotyping, sequencing or
- annotation, other factors may be contributing. There is for example growing evidence
- 69 supporting the hypothesis that many apparently Mendelian phenotypes are caused

⁷⁰ by the interaction of multiple variants in more than one locus.⁷⁻¹¹ Uncovering such

71 genetic interactions has the potential to provide insights not only into disease

72 mechanisms and diagnostics but also into phenomena like incomplete penetrance

73 and variable expressivity.¹²⁻¹⁴

74

75 There are many patterns through which genetic changes in more than one gene can 76 synergistically shape a phenotype. A simple scenario, would involve two 77 heterozygous variants in two distinct loci cooperating to mediate disease (when each 78 individual variant in isolation fails to explain the clinical presentation). Only a small number of cases with this specific form of digenic inheritance have been described¹⁵⁻ 79 80 ¹⁷, the majority detected through gualitative approaches involving variant segregation 81 analyses in a small number of families. In these cases, interaction-based models 82 have generally been used to provide a post hoc explanation of the observed 83 phenomena. By contrast, we describe a quantitative, case-control approach that 84 allows obtaining statistical evidence of digenic patterns. We focused on specific 85 genotypes in the TYR and OCA2 genes; biallelic variants in each of these two genes

It is made available under a CC-BY-ND	4.0 International license .
---------------------------------------	-----------------------------

86	are associated with albinism, a clinically and genetically heterogeneous group of
87	conditions characterised by reduced levels of melanin pigment. Key features of
88	albinism include visual abnormalities and under-development of the central retina
89	(<i>i.e.</i> the fovea); skin and/or hair hypopigmentation may also be present. ¹⁸ Building on
90	recent work ¹⁹⁻²² , we aimed to advance our understanding of the genetic complexity
91	of this rare disorder.
92	
93	
94	RESULTS & DISCUSSION
95	
96	A cohort of 1,015 people with albinism underwent testing of ≤19 albinism-related
97	genes; these individuals were not known to be related and had predominantly
98	European-like ancestries (Supplementary Data 1). A further 105 probands with
99	albinism were identified in the Genomics England 100,000 Genomes Project
100	dataset. ²³ A "control" cohort of 29,451 unrelated individuals that had no recorded
101	diagnosis or features of albinism was also identified in this resource (Fig.1,
102	Supplementary Table 1, Methods).
103	

It is made available under a CC-BY-ND 4.0 International license .



• analysis repeated and expanded in an independent cohort (UK Biobank)

Figure 1. Outline of the case-control study design.

A case-control analysis was performed to gain insights into the role of genotypes involving dual heterozygosity for *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330] in albinism. These two missense changes were selected as they are the commonest albinism-related variants in European-like populations.

The majority of participants in the "case" cohort (1,015/1,120) were identified through the database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. All these probands had at least one key ocular feature of albinism, *i.e.* nystagmus or prominent foveal hypoplasia (see Methods). The remaining 105/1,120 cases were identified through the Genomics England 100,000 Genomes Project dataset and had a diagnosis of albinism or partial/ocular albinism. The "control" cohort included 29,451 unrelated individuals from the Genomics England 100,000 Genomes Project dataset, none of whom had a recorded diagnosis of albinism.

It is made available under a CC-BY-ND 4.0 International license .

To reduce the likelihood of obtaining spurious signals due to population stratification effects or due to the presence of albinism-related variants other than the two studied changes, we focused only on individuals who: (i) were projected to have European-like ancestries; (ii) did not have a genotype in keeping with a molecular diagnosis of albinism; (iii) were not heterozygous for a pathogenic or a likely pathogenic variant in *TYR* or *OCA2* (excluding *TYR*:c.1205G>A and *OCA2*:c.1327G>A). The following two covariates were used: sex and number of common albinism-associated alleles, *i.e.* DNA sequence alterations in the genomic locations corresponding to *TYR*:c.-301C>T [rs4547091] and *TYR*:c.575C>A (p.Ser192Tyr) [rs1042602]. These two variants have been previously shown to modify the effect of *TYR*:c.1205G>A which is a common missense change that can act as a "hypomorphic" variant.¹⁹⁻²¹

To assess the robustness of the findings we performed additional analyses in subsets of the cohort. Validation studies in an independent cohort (UK Biobank) were also conducted.

100K_GP, Genomics England 100,000 Genomes Project; het, heterozygous; UKB, UK Biobank. *TYR* and *OCA2* variant numbering was based on the transcripts with the following identifiers: NM_000372.5/ENST00000263321.6. and NM_000275.3/ENST00000354638.8.

105

106 Searching for genetic elements underlying digenic traits may be carried out at the

107 level of genes, genotypes or DNA variants. It is noted that a given pair of DNA

108 variants comprises up to nine pairs of genotypes while a given gene may contain a

109 large number of variants. Each of these search strategies has inherent advantages

and pitfalls.²⁴ We opted for a genotype-based approach that offers a high level of

- 111 precision and is more likely to provide insights that can be used for clinical genome
- 112 interpretation.

113

114 Our genotype-based analysis focused on two prevalent albinism-related changes,

115 *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443lle)

116 [rs74653330]. We hypothesised that when these two missense variants are both

117 present in the heterozygous state ("dual heterozygosity"), their interaction is driving

- 118 the pathology observed in albinism. Notably, both these changes have been shown
- 119 to reduce the activity of their respective protein products *in vitro*.²⁵⁻²⁹ Further,
- 120 previous studies have pointed to a functional interaction between the TYR and OCA2
- 121 proteins: the latter has a role in the pH regulation of the melanosome which, in turn,

It is made available under a CC-BY-ND 4.0 International license .

122	can affect the catalytic activity of the former (<i>i.e.</i> tyrosinase, the rate-limiting enzyme
123	for the synthesis of melanin in the melanosomes of retinal pigment epithelia and
124	melanocytes). ^{18,30} Both TYR:c.1205G>A and OCA2:c.1327G>A have been
125	implicated in albinism when <i>in trans</i> with pathogenic changes in the same gene. ^{21,31}
126	Also, multiple associations have been recorded for these two variants including with
127	skin/hair pigmentation and skin cancer. ³² It is noted that these two changes were
128	chosen as they are the two commonest albinism-related variants in populations of
129	European-like ancestries, a feature that can help mitigate potential issues with
130	statistical power. It is also highlighted that the minor allele frequencies of the
131	TYR:c.1205G>A and OCA2:c.1327G>A changes in European populations are 27%
132	and 0.3% respectively (Non-Finnish European subset of the Genome Aggregation
133	Database [gnomAD] v2.1.1).33 The particularly common TYR:c.1205G>A change
134	has been associated with incomplete penetrance (and variable expressivity), and
135	previous studies have pointed to the potential for other TYR variants to modify its
136	effect. ^{19-21,25,34-36}
137	
138	We used Firth regression analysis ^{37,38} to study how dual heterozygosity for

139 TYR:c.1205G>A and OCA2:c.1327G>A affects the probability of receiving a

140 diagnosis of albinism ("risk of albinism"). This logistic regression approach has been

141 designed to handle small, imbalanced datasets (which are common in studies of rare

142 conditions) and allows for adjustment of key covariates (which is not possible in

143 contingency table methods) (Fig.1). To increase the genetic similarity³⁹ between the

144 compared cohorts (cases and controls) and to reduce the impact of albinism-related

145 variants other than the two studied changes (*TYR*:c.1205G>A and

146 OCA2:c.1327G>A), we excluded from our analysis individuals that: (i) did not have

It is made available under a CC-BY-ND 4.0 International license .

- 147 European-like ancestries, (ii) were found to have genotypes in keeping with a
- 148 molecular diagnosis of albinism, (iii) carried pathogenic or likely pathogenic variants
- in the TYR or OCA2 gene (with the exception of TYR:c.1205G>A and
- 150 OCA2:c.1327G>A). The resulting case and control cohorts included 204 and 20,350
- 151 individuals respectively. These were used to perform case-control comparisons
- 152 between the following genotype groups:
- group A (reference group): homozygous for TYR:c.1205= and OCA2:c.1327=
- group B (single TYR heterozygote group): heterozygous for TYR:c.1205G>A and
- 155 homozygous for OCA2:c.1327=.
- group C (single OCA2 heterozygote group): homozygous for TYR:c.1205G= and
- 157 heterozygous for OCA2:c.1327G>A.
- *group D* (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and
 OCA2:c.1327G>A variant combination.
- 160 These groups correspond to different levels of dysfunction of the TYR and OCA2
- 161 molecules and the findings of the regression analysis revealed a synergistic
- 162 potentiation of the changes at the two loci (Fig.2, Supplementary Fig.1a and
- 163 Supplementary Table 2). The point estimate for the odds of receiving a diagnosis of
- albinism in individuals who are heterozygous for the *TYR*:c.1205G>A and
- 165 OCA2:c.1327G>A variant combination was 12.8 (the 95% confidence interval was
- 166 6.0 24.7 and the p-value was 2.1×10^{-8}).

It is made available under a CC-BY-ND 4.0 International license .

g	enotype			
<i>TYR:</i> c.1205G>A (p.Arg402GIn)	OCA2: c.1327G>A (p.Val443lle)	group	number of probands (cases / controls)	probability of receiving a diagnosis of albinism (odds ratio, log ₁₀)
GG	GG	A	103 / 10,369	
AG	GG	В	71 / 8,011	-•-1
GG	AG	С	7 / 158	
AG	AG	D	10 / 128	
			0.	.1 1 10 100

Figure 2. The combination of the *TYR*:c.1205G>A (p.Arg402GIn) and *OCA2*:c.1327G>A (p.Val443Ile) variants in a dual heterozygous state confers susceptibility to albinism.

The probability of receiving a diagnosis of albinism (*i.e.* the risk of albinism) was calculated for the following genotype groups:

- group A (reference group): homozygous for TYR:c.1205= and OCA2:c.1327=
- **group B** (single TYR heterozygote group): heterozygous for TYR:c.1205G>A and homozygous for OCA2:c.1327=
- group C (single OCA2 heterozygote group): homozygous for TYR:c.1205G= and heterozygous for OCA2:c.1327G>A
- **group D** (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA*2:c.1327G>A variant combination.

A log₁₀ scale is used. The circle in the middle of each horizontal line (95% confidence interval) represents the point estimate of each odds ratio. Group A was used as the reference group to which all other groups were compared using Firth regression analysis (*i.e.* the odds ratio for this group was fixed at 1). Further information including numerical data can be found in Supplementary Table 2.

- 169 To increase confidence in these observations, we performed additional analyses in
- 170 an independent cohort, the UK Biobank.⁴⁰ We found that UK Biobank volunteers who
- 171 were heterozygous for the TYR:c.1205G>A and OCA2:c.1327G>A variant
- 172 combination had not only a higher chance of receiving a diagnosis of albinism
- 173 (OR>6.9, p-value=0.0004) but also had, on average, slightly worse visual acuity and

It is made available under a CC-BY-ND 4.0 International license .

174 marginally thicker central retina (the respective Kruskal-Wallis p-values were 1.4 x

175 10⁻³ and 8.2 x 10⁻⁴; Fig.3 and Supplementary Tables 3-6). It is noted that visual

acuity and central retinal thickness are quantitative endophenotypes of albinism and

177 these findings suggest that the studied *TYR*/OCA2 variant combination is both

178 contributing to the genetic architecture of albinism and having a role in the

179 development of the visual system in individuals from the general population.

180

genotype		a	b	c	
<i>TYR:</i> c.1205G>A (p.Arg402GIn)	OCA2: c.1327G>A (p.Val443lle)	group	probability of receiving a diagnosis of albinism (odds ratio, log ₁₀)	left visual acuity (LogMAR)	left central retinal thickness (μm)
GG	GG	A			
AG	GG	В			
GG	AG	с			
AG	AG	D			
		0	.1 1 10 100	-0.5 0.0 0.5 1.0	200 250 300 350

Figure 3. The combination of the *TYR*:c.1205G>A (p.Arg402GIn) and *OCA2*:c.1327G>A (p.Val443IIe) variants in a dual heterozygous state is associated with (a) a higher probability of receiving an albinism diagnosis (*i.e.* a higher risk of albinism), (b) lower visual acuity and (c) increased central retinal thickness in UK Biobank participants.

The following genotype groups were studied:

- group A (reference group): homozygous for TYR:c.1205= and OCA2:c.1327=
- **group B** (single TYR heterozygote group): heterozygous for TYR:c.1205G>A and homozygous for OCA2:c.1327=
- **group C** (single OCA2 heterozygote group): homozygous for TYR:c.1205G= and heterozygous for OCA2:c.1327G>A
- *group D* (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant combination.

It is noted that individuals with albinism tend to have reduced visual acuity (*i.e.* higher LogMAR value than 0.2) and increased central retinal thickness (due to underdevelopment of the fovea). More details on the utilised approach can be found in the Methods and in Supplementary Fig.2 and 3. Further information including numerical data can be found in Supplementary Tables 3-6.

- 182 We provide evidence that the *TYR*:c.1205G>A and *OCA2*:c.1327G>A changes
- appear to have a joint effect when each is encountered in the heterozygous state.

It is made available under a CC-BY-ND 4.0 International license .

184	However, the interpretation of this variant combination in clinical diagnostic settings
185	should be approached cautiously. Although the detected effect size (odds ratio) is
186	significant, it would be more in keeping with a predisposing ⁴¹ rather than a
187	pathogenic ⁴² genotype. Further, while it is tempting to view our observations as an
188	example of a digenic pattern, this would have reductionist connotations; interactions
189	are ubiquitous in nature and we expect that increased sample sizes will elucidate
190	longer "chains" of interconnected genetic variation. It is thus plausible that the effect
191	size of the studied genotype will increase when further genetic changes that impact
192	on tyrosinase function or melanosome pH are added to the model. Indeed,
193	observations in the presented data already point to this possibility (Supplementary
194	Fig.3; Supplementary Data 2 and 3).
195	
196	One limitation of this study is our inability to match stringently the albinism cases with
197	the unaffected controls, especially in terms of genetic background. ⁴³ Although recent
198	ancestry was considered, our analysis was imperfect as it was not possible to
199	reliably assign genetic ancestry to most albinism cases. We used a combination of
200	orthogonal approaches to evaluate the robustness and generalisability of our
201	findings. First, we used 35 presumed neutral single-nucleotide variants to calculate
202	the genomic inflation factor lambda $(\lambda GC)^{44,45}$; the λ_{median} was found to be 1.04, in
203	keeping with limited confounding by ancestry (Supplementary Table 7).
204	Subsequently, we performed a targeted secondary analysis using only Genomics
205	England 100,000 Genomes Project data which allowed us to study case and control
206	groups of high genetic similarity. The results supported our key findings and

207 $\,$ increased confidence in the validity of the detected associations (Supplementary

Fig.1b and Supplementary Table 8). Another potential caveat is that the detected

It is made available under a CC-BY-ND 4.0 International license .

209	signal in dual heterozygotes for TYR:c.1205G>A and OCA2:c.1327G>A could, to a
210	degree, be driven by undetected pathogenic variation in either TYR or OCA2. This
211	cannot be excluded despite the fact that medical-grade genetic analyses were
212	undertaken. It can be argued however that significant confounding is unlikely
213	especially given that the effect of dual heterozygosity for TYR:c.1205G>A and
214	OCA2:c.1327G>A appears to be consistently greater than that of genotypes
215	involving heterozygosity for either TYR:c.1205G>A or OCA2:c.1327G>A alone
216	(Supplementary Tables 2, 3, 8 and 9). Nonetheless, statistically significant results
217	were also obtained for individuals carrying the OCA2:c.1327G>A change in
218	heterozygous state (without TYR:c.1205G>A) and future studies will provide further
219	insights into the extent to which this change alone drives the observed signal.
220	
221	In conclusion, we have shown that dual heterozygosity for a TYR and an OCA2
222	variant confers susceptibility to albinism. Shedding light into this and other variant
223	interactions is expected to increase our understanding of the pathways and cellular
224	processes affected in albinism. Notably, the concepts discussed herein are likely to
225	be relevant to other rare disorders, and systems-based approaches using biological
226	modules are expected to narrow the molecular diagnostic gap. Future work will focus
227	on increasing sample sizes, embracing more diverse populations and searching for
228	high-order interactions by considering more than two variants at a time.

229

It is made available under a CC-BY-ND 4.0 International license .

230 METHODS

231	
232	Cohort characteristics and genotyping
233	University Hospital of Bordeaux albinism cohort
234	Individuals with albinism were identified through the database of the University Hospital of Bordeaux
235	Molecular Genetics Laboratory, France. This is a national reference laboratory that has been
236	performing genetic testing for albinism since 2003 and has been receiving samples from individuals
237 238	predominantly based in France (or French-administered overseas territories).
239	Information on the dermatological and ophthalmological phenotypes was available for all affected
240	individuals. The relevant clinical data were assessed independently by two clinicians with experience
241	in the field of albinism and only cases with a consensus clinical impression of albinism were included.
242	It is noted that and each of these cases had at least one of the key ocular features of albinism, <i>i.e.</i>
243	infantile nystagmus or absence of a foveal pit (prominent foveal hypoplasia) (Supplementary Table
244	10). No pre-screening based on genotype was undertaken other than selecting individuals in whom
245	position c301 of TYR was sequenced. Only individuals who were not knowingly related were
246	included.
247	
248	Genetic testing, bioinformatic analyses, and variant interpretation were performed as previously
249	described. ^{20,21} Briefly, most participants had gene-panel testing of ≤19 genes associated with albinism
250	(C100RF11, GPR143, HPS 1 to 10, LYST, OCA2, SLC38A8, SLC24A5, SLC45A2, TYR, TYRP1)
251	using IonTorrent platforms. High-resolution array-CGH (comparative genomic hybridization) was used
252	to detect copy number variants in these genes. All genetic changes of interest were confirmed with an
253	alternative method (e.g. Sanger sequencing or quantitative PCR). Clinical interpretation of variants
254	was performed using criteria consistent with the 2015 American College of Medical Genetics and
255	Genomics (ACMG) best practice guidelines. ⁴² It is noted that genetic findings in this cohort have been
256	partly reported in previous publications from our group ^{19,22} and that comprehensive genomic testing
257	(including single-nucleotide variant and copy number variant analysis involving the aforementioned 19
258 259	albinism-related genes) was performed in all cases that remained unsolved.
260	Due to the limited number of genomic loci screened in this cohort, it was not possible to reliably

261 assess genetic ancestry and to "objectively" assign individuals to genetic ancestry groups. Attempting

It is made available under a CC-BY-ND 4.0 International license .

to mitigate this, we processed available data on self-identified ethnicity that were collected through

263 questionnaires. Responses were inspected and stratification into five broad continental groups

- 264 (European, African, Admixed American, East Asian, South Asian) was performed.
- 265
- 266
- 267

268 Genomics England 100,000 Genomes Project cohort

269 Clinical and genomic data from the Genomics England 100,000 Genomes Project were accessed

270 through a secure Research Environment that is available to registered users. This dataset was

- 271 collected as part of a national genome sequencing initiative.⁴⁶ Enrolment was coordinated by
- 272 Genomics England Limited, and participants were recruited mainly at National Health Service (NHS)

273 Hospitals in the UK.²³ Clinical information was recorded in Human Phenotype Ontology (HPO)⁴⁷ terms

274 and International Classification of Diseases (ICD) codes. Genome sequencing was performed in DNA

samples from ≥78,195 individuals using Illumina HiSeq X systems (150 base-pair paired-end format).

276 Reads were aligned using the iSAAC Aligner v03.16.02.19 and small variants were called using

277 Starling v2.4.7.48 Structural variants and long indel (>50bp) calling was performed with Manta v0.28.0,

and copy number variants (CNVs) were called with Canvas v1.3.1.^{49,50} Aggregation of single-sample

279 gVCFs was performed using the Illumina software gVCF genotyper v2019.02.29;

280 normalisation/decomposition was implemented by vt v0.57721⁵¹. The multi-sample VCF was then split

281 into 1,371 roughly equal chunks to allow faster processing and the loci of interest were queried using

282 bcftools v1.9⁵² (see https://research-help.genomicsengland.co.uk/display/GERE/ for further

283 information). Only variants that passed standard quality control criteria were processed (including the

284 criteria discussed in <u>https://re-docs.genomicsengland.co.uk/site_gc/</u> and criteria analogous to those

285 outlined in https://re-docs.genomicsengland.co.uk/somatic_sv/#note-on-variant-calling). In addition,

we filtered out genotypes with: genotype score <20; read depth <10; allele balance <0.2 and >0.8 for

287 heterozygotes; allele balance >0.1 or <0.9 for homozygotes (reference and alternate, respectively).

288 Genomic annotation was performed using Ensembl VEP⁵³. Variants with a "total" minor allele

frequency (MAF) <1% in the Genome Aggregation Database (gnomAD v2.1.1)³³ and a "disease-

290 causing" (DM) label in the Human Gene Mutation Database (HGMD) v2021.2⁵⁴ were flagged (and are

291 hitherto referred to as "HGMD-listed variants"). In depth manual curation of all detected rare (*i.e.*

292 MAF < 1%) variants in *TYR* and OCA2 was undertaken and these changes were classified according

to the 2015 American College of Medical Genetics and Genomics (ACMG) best practice guidelines.⁴²

It is made available under a CC-BY-ND 4.0 International license .

294	
295	Ancestry inference was performed in the Genomics England 100,000 Genomes Project cohort using
296	principal component analysis. Data from the 1000 genomes project (phase 3) dataset were used and
297	five broad super-populations were projected (European, African, Admixed American, East Asian,
298	South Asian) (further information on this can be found online at https://research-
299 300	help.genomicsengland.co.uk/display/GERE/Ancestry+inference).
301	We focused on a pre-determined subset of the Genomics England 100,000 Genomes Project dataset
302	that includes only unrelated probands (n=29,556). Of these, 105 had a diagnosis of albinism, <i>i.e.</i> the
303	ICD-10 term "Albinism" [E70.3] and/or the HPO terms "Albinism" [HP:0001022], "Partial albinism"
304	[HP:0007443] or "Ocular albinism" [HP:0001107] were assigned (Supplementary Table 10). Together
305	with the University Hospital of Bordeaux cases, these 105 probands formed the "case" cohort. The
306	remaining 29,451 probands had no recorded diagnosis or phenotypic features of albinism and formed
307	the "control" cohort. We note that comprehensive ophthalmic phenotyping was not routinely
308	undertaken in Genomics England 100,000 Genomes Project participants. We cannot therefore be
309	certain that a small number of individuals with mild/subclinical forms of albinism are not included in
310	the control cohort.
311	
312	Case control enclusio to estimate the probability of an albiniam dispussio
212	
314	The effect of dual heterozygosity for TYR:c.1205G>A (p.Arg402Gin) [rs1126809] and
315	OCA2:c.1327G>A (p.Val443IIe) [rs74653330] on the probability of receiving a diagnosis of albinism
316	(<i>i.e.</i> the albinism risk) was estimated using data from the University Hospital of Bordeaux albinism
317	cohort and the Genomics England 100,000 Genomes Project dataset. A case-control analysis of a
318	binary trait (presence/absence of albinism) was conducted assuming a recessive model. Logistic
319	regression using the Firth bias reduction method ^{37,38} was utilised (as implemented in "logistf" R
320	package). The following parameters were set:
321	• inclusion criteria: the analysis was conducted only on study subjects who: (i) were projected to
322	
	have European-like ancestries, (ii) were not found to have genotypes in keeping with a molecular
323	have European-like ancestries, (ii) were not found to have genotypes in keeping with a molecular diagnosis of albinism, (iii) carried no pathogenic or likely pathogenic variants in the <i>TYR</i> or <i>OCA2</i>
323 324	have European-like ancestries, (ii) were not found to have genotypes in keeping with a molecular diagnosis of albinism, (iii) carried no pathogenic or likely pathogenic variants in the <i>TYR</i> or <i>OCA2</i> gene (with the exception of the two studied changes <i>TYR</i> :c.1205G>A and <i>OCA2</i> :c.1327G>A).

It is made available under a CC-BY-ND 4.0 International license .

326 327	Ancestry: To increase the genetic similarity between the studied case and control cohorts, we focused
328	on individuals who were likely to fall within the same broad ancestral group. It is highlighted though
329	that the utilised approach was imperfect as it was not possible to objectively determine genetic
330	ancestry in individuals from the University Hospital of Bordeaux albinism cohort (as mentioned above,
331	self-identified ethnicity was instead used as a surrogate). Confounding by ancestry (i.e. population
332	stratification) is therefore a possibility. ³⁹ We attempted to quantify this by calculating the genomic
333	inflation factor lambda (λ GC). A total of 35 single-nucleotide variants were selected using a previously
334	described approach (see Supplementary Table 7 and ¹⁸). Case-control comparisons were then made
335	for each of these 35 λ GC markers using Firth regression analysis. The resulting test statistics were
336	used to calculate the median value of λGC . ¹⁸
337 338	Albinism-related genotypes: To reduce the likelihood of obtaining spurious results due to the impact of
339	albinism-related variants other than the two studied changes (TYR:c.1205G>A and
340	OCA2:c.1327G>A), we excluded individuals who carried genotypes consistent with a molecular
341	diagnosis of albinism. This included study subjects with:
342	homozygous pathogenic or likely pathogenic HGMD-listed variants in autosomal albinism-related
343	genes (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10ORF11, HPS 1 to 10, LYST, SLC38A8),
344	• presumed biallelic pathogenic or likely pathogenic HGMD-listed variants in autosomal albinism-
345	related genes (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10ORF11, HPS 1 to 10, LYST,
346	SLC38A8),
347	• hemizygous pathogenic or likely pathogenic HGMD-listed variants in GPR143 or FRMD7,
348	• the TYR c.[-301C;575C>A;1205G>A] or TYR c.[-301C;575C;1205G>A] albinism-related
349	haplotype ¹⁹ in homozygous state
350	• the TYR c.[-301C;575C>A;1205G>A] or TYR c.[-301C;575C;1205G>A] albinism-related
351	haplotype in heterozygous state plus a heterozygous pathogenic or likely pathogenic variant in
352	TYR.
353 354	We also excluded from our analysis individuals who were found to carry pathogenic or likely
355	pathogenic variants in the TYR or OCA2 gene (in heterozygous state). Small scale genetic changes
356	(with the exception of TYR :c.1205G>A and $OCA2$:c 1327G>A). conv number and structural variants
357	were factored in.

It is made available under a CC-BY-ND 4.0 International license .

358 359	Common albinism-associated alleles. The effect of one of the studied changes (TVR c $1205G > A$) has
360	been provide by shown to be modified by the following two variants $^{19-21,25,34-36}$ which have been added
361	as a covariate to the regression model:
262	
362	• TYR c301C>1 [rs4547091], located in the TYR promoter; the derived, non-ancestral allele c
363	301C (or c301=) has a MAF of ~60% in non-Finnish European (NFE) populations in the Genome
364	Aggregation Database (gnomAD v2.1.1) ³⁵ ;
365	• TYR c.575C>A (p.Ser192Tyr) [rs1042602], which has a MAF of ~36% in gnomAD NFE
366	populations.
367	It is highlighted that the TYR c301= and the TYR c.575C>A (p.Ser192Tyr) alleles are frequently
368	found in linkage disequilibrium so the presence of the latter would, in most cases, suggest the
369	presence of the former on the same haplotype.
370	
371	Case-control comparisons between TYR/OCA2 genotype groups: Our primary analysis focused on
372	performing case-control comparisons between groups of genotypes that include different alleles at
373	positions <i>TYR</i> :c.1205 and <i>OCA2</i> :c.1327. These groups were:
374	• group A (reference group): homozygous for <i>TYR</i> :c.1205= and <i>OCA2</i> :c.1327=
375	• group B (single TYR heterozygote group): heterozygous for <i>TYR</i> :c.1205G>A and homozygous for
376	OCA2:c.1327=.
377	• group C (single OCA2 heterozygote group): homozygous for <i>TYR</i> :c.1205G= and heterozygous for
378	OCA2:c.1327G>A.
379	• group D (dual heterozygote group): heterozygous for the <i>TYR</i> :c.1205G>A and <i>OCA2</i> :c.1327G>A
380	variant combination.
381	Analyses were also conducted in individuals who were found to be homozygous for TYR:c.1205G>A
382	(but are considered unsolved, <i>i.e.</i> they do not carry the TYR c.575C>A or the TYR c301= variant in
383	the homozygous state); these were split into two groups:
384	• group E: homozygous for TYR:c.1205G>A and OCA2:c.1327=;
385	• group F: homozygous for TYR:c.1205G>A and heterozygous for OCA2:c.1327G>A
386	
381	Group A was used as the reference group to which all other groups were compared using Firth
388	regression analysis (<i>i.e.</i> the odds ratio for this group was fixed at 1).

It is made available under a CC-BY-ND 4.0 International license .

389	
390	The primary analysis focused on a mixed case cohort (including 174 probands from the University
391	Hospital of Bordeaux cohort and 31 cases from the Genomics England 100,000 Genomes Project
392	dataset) and a control cohort from the Genomics England 100,000 Genomes Project dataset (20,350
393	unrelated individuals) (Fig.2; Supplementary Fig.1a; Supplementary Table 2). A secondary analysis
394	focusing only on individuals from the Genomics England 100,000 Genomes Project dataset (31
395	cases, 20,350 controls) was also undertaken (Supplementary Fig.1b; Supplementary Table 8).
396	
397 398	Replication of findings in the LIK Biobank cohort
570	
399	The effect of dual heterozygosity for TYR:c.1205G>A and OCA2:c.1327G>A was studied in the UK
400	Biobank. UK Biobank is a biomedical resource containing in-depth genetic and health information
401	from >500,000 individuals from across the UK. ⁴⁰ A subset of UK Biobank volunteers underwent
402	enhanced phenotyping including visual acuity testing (131,985 individuals) and imaging of the central
403	retina (84,748 individuals) ⁵⁵ ; the latter was obtained using optical coherence tomography (OCT), a
404	non-invasive imaging test that rapidly generates cross-sectional retinal scans at micrometre-
405	resolution.56,57 All UK Biobank volunteers whose data were analysed as part of this study were
406	imaged using the 3D OCT-1000 Mark II device (Topcon, Japan); the relevant methodology has been
407	previously described. ⁵⁵ Notably, the diagnosis of albinism has been assigned to 39 UK Biobank
408	participants (ICD-10 term "Albinism" [E70.3] in data field 41270 or resource 591) (Supplementary
409	Table 10).
410	Aiming to proceed the reductions of the results in the combined University Despite of Developmy and
411	Aiming to assess the robustness of the results in the combined University Hospital of Bordeaux and
412	Genomics England 100,000 Genomes Project dataset, we performed case-control analyses in UK
413	Biobank volunteers. We focused on individuals who were estimated by principal component analysis
414	to have European-like ancestries (data field 22006). First, genotyping array data were used to obtain
415	genotypes for the TYR:c.1205G>A variant and OCA2:c.1327G>A variant (data field 22418 including
416	information from the Applied Biosystems UK Biobank Axiom Array containing 825,927 markers). Only
417	individuals reliably genotyped at both sites were retained. Aiming to reduce the likelihood of obtaining
418	spurious signals due to the presence of albinism-related variants other than the two studied changes

419 (TYR:c.1205G>A and OCA2:c.1327G>A), we excluded UK Biobank participants whose genotyping

medRxiv preprint doi: https://doi.org/10.1101/2023.01.19.23284597; this version posted December 18, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

420 array data (data field 22418) suggested that they carried an HGMD-listed variant in an albinism-421 related gene (Supplementary Data 4). 422 423 We used Firth logistic regression to perform case-control comparisons between genotype groups A-D. 424 Sex and the number of common albinism-associated alleles were used as covariates (Fig.3a; 425 Supplementary Fig.2; Supplementary Table 3). 426 427 Given that reduced visual acuity and increased central retinal thickness (due to underdevelopment of 428 the fovea) are two hallmark features of albinism we investigated the impact of selected TYR/OCA2 429 variant combinations on these two quantitative traits. Aiming to reduce the likelihood of obtaining 430 spurious signals due to the presence/impact of ophthalmic conditions/features not related to albinism, 431 we excluded all UK Biobank volunteers that did not have the ICD-10 term "Albinism" [E70.3] and were 432 assigned an ophthalmology-related ICD-10 code ("Chapter VII Diseases of the eye and adnexa"). 433 434 We first obtained data on the left LogMAR visual acuity for UK Biobank volunteers (data field 5201, 435 "instance 0" datasets). These visual acuity measurements were then used to compare visual 436 performance between groups of volunteers with selected TYR/OCA2 genotype combinations 437 (genotype groups A-D) (Supplementary Fig.3). As the obtained distributions deviated from normality, 438 the Kruskal-Wallis test was used. Pair-wise comparisons were performed and the p-values were 439 adjusted using the Benjamini-Hochberg method (Fig.3b; Supplementary Table 4). Additional analyses 440 using a linear regression approach were also conducted; sex and the number of common albinism-441 associated alleles were included as covariates (Supplementary Table 5). 442 443 We then obtained central retinal thickness measurements from UK Biobank OCT images using the 444 "macular thickness at the central subfield" data field (27802; defined as the average distance between 445 the hyperreflective bands corresponding to the RPE and the internal limiting membrane (ILM), across 446 the central 1 mm diameter circle of the ETDRS grid) for UK Biobank volunteers.⁵⁸ The obtained 447 measurements were subsequently used to compare central retinal thickness between groups of UK 448 Biobank volunteers with selected TYR/OCA2 genotype combinations (groups A-D). As some of the 449 obtained distributions deviated from normality, the Kruskal-Wallis test was used. Pair-wise 450 comparisons were performed and the p-values were adjusted using the Benjamini-Hochberg method 451 (Fig.3c; Supplementary Table 4). Additional analyses using a linear regression approach were also

It is made available under a CC-BY-ND 4.0 International license .

452 conducted; sex and the number of common albinism-associated alleles were included as covariates 453 (Supplementary Table 6). 454 455 It is noted that we opted to perform all UK Biobank analyses on left eye data. This is because, as per 456 study protocol⁵⁵, the left eye was tested after the right eye, potentially making the measurements from 457 the left side less prone to artifacts (as the participants were more familiar with the test). 458 459 460 Additional analysis in the University Hospital of Bordeaux albinism cohort 461 Further analyses were undertaken using only data from individuals in the University Hospital of 462 Bordeaux albinism cohort. After excluding study subjects who did not report having European-like 463 ancestries, the cohort was split into cases with and cases without a molecular diagnosis of albinism 464 (*i.e.* "solved" and "unsolved"). Individuals without a molecular diagnosis who carried heterozygous 465 pathogenic or likely pathogenic variants in the TYR or OCA2 gene (with the exception of the two 466 studied changes TYR:c.1205G>A and OCA2:c.1327G>A) were then removed from the unsolved 467 group. The patterns observed in genotype groups A-D were then assessed using both contingency 468 table methods and Firth regression analyses (Supplementary Table 9). 469

470

471 Ethics approval

472 Informed consent was obtained from all participants or their parents in the case of minors. The study 473 of individuals from the University Hospital of Bordeaux albinism cohort has been approved by the 474 relevant local ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III, 475 Bordeaux, France). The informed consent process for the Genomics England 100,000 Genomes 476 Project has been approved by the National Research Ethics Service Research Ethics Committee for 477 East of England – Cambridge South Research Ethics Committee. The UK Biobank has received 478 approval from the National Information Governance Board for Health and Social Care and the 479 National Health Service North West Centre for Research Ethics Committee (Ref: 11/NW/0382). All 480 investigations were conducted in accordance with the tenets of the Declaration of Helsinki. 481

It is made available under a CC-BY-ND 4.0 International license .

482 DATA AVAILABILITY

- 483
- 484 The Genomics England 100,000 Genomes Project dataset is available under
- 485 restricted access through a procedure described at
- 486 https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-
- 487 access. The UK Biobank dataset is available under restricted access through a
- 488 procedure described at http://www.ukbiobank.ac.uk/using-the-resource/. All other
- 489 data supporting the findings of this study are available within the article (including its
- 490 Supplementary Information files).

491

492

493 CODE AVAILABILITY

494

- The scripts used to analyse the datasets included in this study are available
- 496 at https://github.com/davidjohngreen/tyr-oca2.

497

It is made available under a CC-BY-ND 4.0 International license .

499 **REFERENCES**

500		
501	1.	Boycott, K.M. et al. A diagnosis for all rare genetic diseases: The horizon and the next
502		frontiers. <i>Cell</i> 177 32-37 (2019) doi: 10.1016/i.cell.2019.02.040
503	2	Splinter K et al. Effect of genetic diagnosis on patients with previously undiagnosed disease
504		<i>N Engl J Med.</i> 379 , 2131-2139 (2018), doi: 10.1056/NEJMoa1714458.
505	3.	Posev, J.E. <i>et al.</i> Insights into genetics, human biology and disease gleaned from family
506	0.	based genomic studies. <i>Genet Med.</i> 21 , 798-812 (2019), doi: 10.1038/s41436-018-0408-7.
507	4.	Zurek, B. <i>et al.</i> Solve-RD: systematic pan-European data sharing and collaborative analysis
508		to solve rare diseases. Eur J Hum Genet. 29, 1325-1331 (2021), doi: 10.1038/s41431-021-
509		00859-0
510	5.	100,000 Genomes Project Pilot Investigators. 100,000 Genomes Pilot on rare-disease
511		diagnosis in health care - Preliminary report. N Engl J Med. 385, 1868-1880 (2021). doi:
512		10.1056/NEJMoa2035790.
513	6.	Boycott, K.M. et al. Care4Rare Canada: Outcomes from a decade of network science for rare
514		disease gene discovery. Am J Hum Genet. 109, 1947-1959 (2022). doi:
515		10.1016/j.ajhg.2022.10.002.
516	7.	Schäffer, A.A. Digenic inheritance in medical genetics. J Med Genet. 50, 641-652 (2013). doi:
517		10.1136/jmedgenet-2013-101713.
518	8.	Katsanis, N. The continuum of causality in human genetic disorders. Genome Biol. 17, 233
519		(2016). doi: 10.1186/s13059-016-1107-9.
520	9.	Deltas C. Digenic inheritance and genetic modifiers. <i>Clin Genet.</i> 93 , 429-438 (2018). doi:
521		10.1111/cge.13150.
522	10.	Nachtegael, C. et al. Scaling up oligogenic diseases research with OLIDA: the Oligogenic
523		Diseases Database. Database (Oxford). 2022, baac023 (2022). doi:
524		10.1093/database/baac023.
525	11.	Burkard, M. et al. Accessory neterozygous mutations in cone photoreceptor UNGA3
520		exacerbate UNG channel-associated retinopathy. J Clin Invest. 128, 5663-5675 (2018). doi:
521	10	10.1172/JU96098 Cooper, D.N., Krowersk, M., Belvekrenskee, C., Tuler, Smith, C. & Kehrer, Sowetski, U.
528 520	12.	Cooper, D.N., Krawczak, M., Polychronakos, C., Tyler-Smith, C. & Kenrer-Sawatzki, H.
529		basis of reduced penetraneo in human inherited disease. <i>Hum</i> Canet 122 , 1077 1120 (2012)
531		doi: 10 1007/c00/30-013-1331-2
532	13	Kousi M & Katsanis N Genetic modifiers and oligogenic inheritance. Cold Spring Harb
533	15.	Perspect Med 5, a017145 (2015), doi: 10.1101/cshperspect a017145
534	14	Costanzo M et al Global genetic networks and the genetype-to-obenotype relationship Cell
535	14.	177 85-100 (2019) doi: 10 1016/i cell 2019 01 033
536	15.	Mukheriee, S. <i>et al.</i> Identifying digenic disease genes via machine learning in the
537		Undiagnosed Diseases Network. Am J Hum Genet. 108 , 1946-1963 (2021), doi:
538		10.1016/i.aiha.2021.08.010.
539	16.	Papadimitriou, S. et al. Predicting disease-causing variant combinations. Proc Natl Acad Sci
540		U S A. 116:11878-11887 (2019). doi: 10.1073/pnas.1815601116.
541	17.	Brehm, A. et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS
542		patients promote type I IFN production. J Clin Invest. 125, 4196-4211 (2015). doi:
543		10.1172/JCl81260.
544	18.	Bakker, R. et al. The retinal pigmentation pathway in human albinism: Not so black and white.
545		Prog Retin Eye Res. 91, 101091 (2022). doi: 10.1016/j.preteyeres.2022.101091.
546	19.	Michaud, V. et al. The contribution of common regulatory and protein-coding TYR variants to
547		the genetic architecture of albinism. Nat Commun. 13, 3939 (2022). doi: 10.1038/s41467-022-
548		31392-3.
549	20.	Campbell, P. et al. Clinical and genetic variability in children with partial albinism. Sci Rep. 9,
550		16576 (2019). doi: 10.1038/s41598-019-51768-8.
551	21.	Monterme, S. et al. Mild form of oculocutaneous albinism type 1: phenotypic analysis of
552		compound heterozygous patients with the R402Q variant of the TYR gene. Br J Ophthalmol.
333		103 , 1239-1247 (2019). doi: 10.1136/bjophthalmol-2018-312729
334 555	22.	Lasseaux, E. et al. Molecular characterization of a series of 990 index patients with albinism.
555 556	00	Pigment Cell Ivleianoma Res. 31, 400-474 (2018). dol: 10.1111/pcmr.12688.
550	23.	Caumeiu, ivi. et al. The National Genomic Research Library.
551		https://uui.utg/10.0004/htg.htgshate.4330893.V7 (2017).

558 550	24.	Okazaki, A. & Ott, J. Machine learning approaches to explore digenic inheritance. <i>Trends</i>
560	05	Genet. 30, 1013-1018 (2022). doi: 10.1010/j.10.2022.04.009.
500	25.	Jagindar, K. et al. Molecular analysis of common polymorphisms within the numan tyrosinase
562		Fight the solution of the solution of the solution for the solution of the sol
562	26	Delineko M.B. et al. Oeuleeuteneeue albiniem tune 1: link betueen mutatione, tureeineee
564	20.	Domiska, M.D. et al. Oculoculateous albinism type 1. link between mulations, tytosinase
565		(2017) doi: 10.1111/pomr.12546
566	27	(2017). doi: 10.1111/pcilii.12340. Sviderskava E.V. at al. Complementation of hypepiamentation in p. mutant (pink avad
567	21.	dilution) mayor melanoouton by normal human D aDNA, and defactive complementation by
568		OCA2 mutant sequences. Unvest Dermetel 109 , 20,24 (1007), doi: 10.1111/1522
560		1747 op 10095601
570	20	1/4/.ep12203021 Pollong NIW Eggeber J.E. Lefkewith A.L. Merke M.S. & Conseq. E. An intropollular opion
570	20.	channel critical for pigmontation <i>Elife</i> 3 o(1513 (2014), doi: 10.7554/ol.ife.04543
572	20	Bollono NW Escobar I E & Oancoa E A molanosomal two-poro sodium channol
573	29.	regulates nigmontation. Sei Don 6, 26570 (2016), doi: 10.1038/sron26570
574	30	Payan W. L. & Sturm, P. A. The genetics of human skin and hair nigmontation. Annu Pay
575	50.	Genomics Hum Genet 20 A1-72 (2010) doi: 10.11/6/2001/16/2000-083118-015230
576	21	Landrum M L at al. ClinVar: improving access to variant interpretations and supporting
577	51.	avidence Nucleic Acide Pes 46 D1062-D1067 (2018) dei: 10.1003/per/akv1153
578		Evidence. Nucleic Acids Nes. 40, D1002-D1007 (2010). doi: 10.1030/11di/grx1133.
570	30	Bunjalla A at al The NHCPLERI GWAS Catalog of published gonome-wide association
580	52.	studies targeted arrays and summary statistics 2019 <i>Nucleic Acids Res</i> 47 D1005-D1012
581		(2010) doi: 10.1003/nar/aky1120 [entries for rs1126809 and rs74653330]
582	33	Karczewski K L et al. The mutational constraint spectrum quantified from variation in
583	55.	141 456 humans Nature 581 434-443 (2020) doi: 10.1038/s41586-020-2308-7
584		Intrins for 11-89017961-G-A (GRCh37) and 15-28228553-C-T (GRCh37)]
585	34	Leftus SK at al Hanlotyne-based analysis resolves missing heritability in oculocutaneous
586	54.	albinism type 1B Am I Hum Genet S0002-9297 00169-6 (2023) doi:
587		10 1016/i aiba 2023 05 012
588	35	Lin S et al. Evidence that the Ser192Tvr/Arg402Gln in cis Tvrosinase gene hanlotype is a
589	00.	disease-causing allele in oculocutaneous albinism type 1B (OCA1B) NPJ Genom Med 7 2
590		(2022) doi: 10.1038/s41525-021-00275-9
591	36	Grønskov, K. et al. A pathogenic haplotype, common in Europeans, causes autosomal
592		recessive albinism and uncovers missing heritability in OCA1. Sci Rep. 9, 645 (2019), doi:
593		10.1038/s41598-018-37272-5.
594	37.	Heinze, G. & Schemper, M. A solution to the problem of separation in logistic regression. Stat
595	••••	<i>Med.</i> 21 , 2409-19 (2002), doi: 10.1002/sim.1047.
596	38.	Firth, D. Bias reduction of maximum likelihood estimates. <i>Biometrika</i> , 80 , 27-38 (1993), doi:
597		10.1093/biomet/80.1.27
598	39.	Marchini, J., Cardon, L.R., Phillips, M.S. & Donnelly, P. The effects of human population
599		structure on large genetic association studies. Nat Genet. 36, 512-517 (2004). doi:
600		10.1038/ng1337
601	40.	Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature.
602		562, 203-209 (2018). doi: 10.1038/s41586-018-0579-z.
603	41.	Masson, E. et al. Expanding ACMG variant classification guidelines into a general framework.
604		Hum Genomics. 16, 31 (2022). doi: 10.1186/s40246-022-00407-x.
605	42.	Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint
606		consensus recommendation of the American College of Medical Genetics and Genomics and
607		the Association for Molecular Pathology. Genet Med. 17, 405-424 (2015). doi:
608		10.1038/gim.2015.30.
609	43.	Freedman, M.L. et al. Assessing the impact of population stratification on genetic association
610		studies. Nat Genet. 36, 388-93 (2004). doi: 10.1038/ng1333.
611	44.	Devlin, B. & Roeder, K. Genomic control for association studies. <i>Biometrics</i> . 55, 997-1004
612		(1999). doi: 10.1111/j.0006-341x.1999.00997.x
613	45.	Dadd, T., Weale, M.E. & Lewis, C.M. A critical evaluation of genomic control methods for
614		genetic association studies. Genet Epidemiol. 33, 290-298 (2009). doi: 10.1002/gepi.20379.
615	46.	Turnbull, C. et al. The 100,000 Genomes Project: bringing whole genome sequencing to the

616 NHS. *BMJ* **361**, 1687 (2018). doi: 10.1136/bmj.k1687

617 618	47.	Köhler, S. et al. The Human Phenotype Ontology in 2021. Nucleic Acids Res. 49, D1207– D1217 (2021). doi: 10.1002/par/akaa1042
010	40	
619	48.	Raczy, C. et al. Isaac: uitra-tast whole-genome secondary analysis on Illumina sequencing
620		platforms. Bioinformatics 29, 2041–2043 (2013). doi: 10.1093/bioinformatics/btt314.
621	49.	Chen, X., et al. Manta: rapid detection of structural variants and indels for germline and
622		cancer sequencing applications. <i>Bioinformatics</i> 32 , 1220-1222 (2016). doi:
623		10.1093/bioinformatics/btv710.
624	50.	Roller, E., Ivakhno, S., Lee, S., Royce, T. & Tanner, S. Canvas: versatile and scalable
625		detection of copy number variants. <i>Bioinformatics</i> 32 , 2375-2377 (2016). doi:
626		10.1093/bioinformatics/btw163.
627	51.	Tan, A., Abecasis, G.R. & Kang, H.M. Unified representation of genetic variants.
628		Bioinformatics 31, 2202–2204 (2015). doi: 10.1093/bioinformatics/btv112
629	52.	Danecek, P. <i>et al.</i> Twelve years of SAMtools and BCFtools. <i>Gigascience</i> 10 , giab008 (2021).
630	53.	McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, (2016). doi:
631		10.1186/s13059-016-0974-4
632	54.	Stenson, P.D. et al. The Human Gene Mutation Database (HGMD [®]): optimizing its use in a
633		clinical diagnostic or research setting. Hum Genet. 139, 1197-1207 (2020). doi:
634		10.1007/s00439-020-02199-3.
635	55.	Chua, S.Y.L., et al. Cohort profile: design and methods in the eye and vision consortium of
636		UK Biobank. BMJ Open 9, e025077 (2019).
637	56.	Bouma, B.E. et al. Optical coherence tomography. Nat Rev Methods Primers. 2, 79 (2022).
638		doi: 10.1038/s43586-022-00162-2.
639	57.	Drexler, W. & Fujimoto, J.G. State-of-the-art retinal optical coherence tomography. Prog Retin
640		<i>Eye Res.</i> 27 , 45–88 (2008). doi: 10.1016/j.preteveres.2007.07.005
641	58.	Currant, H. et al. Genetic variation affects morphological retinal phenotypes extracted from
642		UK Biobank optical coherence tomography images. <i>PLoS Genet.</i> 17 , e1009497 (2021). doi:
643		10.1371/journal.pgen.1009497
644		······································
011		
645		
<i>с</i> 1 <i>с</i>		
646		

647 **ACKNOWLEDGEMENTS**

648

- 649 We acknowledge the following sources of funding: the Wellcome Trust
- 650 (224643/Z/21/Z, Clinical Research Career Development Fellowship to P.I.S.;
- 651 200990/Z/16/Z, Transforming Genetic Medicine Initiative to G.C.B.); the UK National
- Institute for Health Research (NIHR) Clinical Lecturer Programme (CL-2017-06-001
- to P.I.S.); Retina UK and Fight for Sight (GR586, RP Genome Project UK Inherited
- 654 Retinal Disease Consortium to G.C.B.); Christopher Green (D.J.G.); the French
- Albinism Association (Genespoir) and the French National Research Agency
- 656 (Agence Nationale de la Recherche; ANR-21-CE17-0041-01 to B.A.).

- The UK Biobank Eye and Vision Consortium is supported by funding from the NIHR
- 659 Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of

It is made available under a CC-BY-ND 4.0 International license .

660	Ophthalmology, the Alcon Foundation and the Desmond Foundation. The complete
661	list of members of this Consortium can be found in the Supplementary Information
662	
663	This research was made possible through access to the data and findings generated
664	by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by
665	Genomics England Limited (a wholly owned company of the Department of Health
666	and Social Care). The 100,000 Genomes Project is funded by the NIHR and NHS
667	England. The Wellcome Trust, Cancer Research UK and the Medical Research
668	Council have also funded research infrastructure. The 100,000 Genomes Project
669	uses data provided by patients and collected by the National Health Service (NHS)
670	as part of their care and support. We acknowledge the contribution of the Genomics
671	England Research Consortium to the 100,000 Genomes Project. The complete list of
672	members of this Consortium can be found in the Supplementary Information.
673	
674	Lastly, we acknowledge the help of Cécile Courdier at the University Hospital of
675	Bordeaux Molecular Genetics Laboratory, Sophie Javerzat at the University of
676	Bordeaux, Dave Gerrard at the University of Manchester, and Claire Hardcastle,
677	Chris Campbell, Steph Barton and Simon Ramsden at the North West of England
678	Genomic Laboratory Hub.

It is made available under a CC-BY-ND 4.0 International license .

679 AUTHOR CONTRIBUTIONS STATEMENT

- 680
- 681 P.I.S. conceived and designed the experiments. The UK Biobank Eye and Vision
- 682 Consortium, T.F., E.B., B.A., G.C.B. and P.I.S provided datasets and analytical tools.
- D.J.G., V.M., E.L., C.P., T.F., B.A. and P.I.S. analysed the data. P.I.S. wrote the
- 684 manuscript with support from D.J.G. All authors critically revised and approved the
- 685 manuscript.
- 686
- 687 G.C.B. and B.A. contributed equally to this work.
- 688
- 689
- 690

691 COMPETING INTERESTS STATEMENT

- 692
- 693 E.B. is a paid consultant and equity holder of Oxford Nanopore, a paid consultant to
- 694 Dovetail, and a non-executive director of Genomics England, a limited company
- 695 wholly owned by the UK Department of Health and Social Care. All other authors
- 696 declare no competing interests.
- 697
- 698

It is made available under a CC-BY-ND 4.0 International license .

699 UK Biobank Eye and Vision Consortium

- 700
- 701 Graeme C. Black^{1,5}, Panagiotis I. Sergouniotis^{1,4,5,6}
- 702
- ¹ Division of Evolution, Infection and Genomics, School of Biological Sciences,
- Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
- 705
- ⁴ European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-
- EBI), Wellcome Genome Campus, Cambridge, UK.
- 708
- ⁵ Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester
- 710 University NHS Foundation Trust, Manchester, UK.
- 711
- ⁶ Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust,
- 713 Manchester, UK.
- 714
- A full list of members appears in the Supplementary Information.



validation:

- analysis repeated in cases and controls from the 100K_GP only
- analysis repeated and expanded in an independent cohort (UK Biobank)



ge	enotype		a	b	C
<i>TYR:</i> c.1205G>A (p.Arg402GIn)	OCA2: c.1327G>A (p.Val443lle)	group	probability of receiving a diagnosis of albinism (odds ratio, log ₁₀)	left visual acuity (LogMAR)	left central retinal thickness (μm)
GG	GG	Α			
AG	GG	В			
GG	AG	С	│		
AG	AG	D	↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓		
		0	1 1 10 100	-0.5 0.0 0.5 1.0	200 250 300 350